 |
|
|
| |
Statin Therapy Reduces Coronary Noncalcified Plaque Volume
in HIV-infected Patients: a Randomized Controlled Trial
|
| |
| |
Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
"Statin therapy not only prevented the progression of coronary atherosclerosis, but it reduced overall plaque volume and especially lipid
laden noncalcified plaque volume compared to placebo........Statin therapy reduced high risk morphology plaques.......Statin therapy
was safe and well-tolerated........Due to technical limitations, statin effects on arterial inflammation by FDG-PET could not be adequately
assessed, however atorvastatin did reduce systemic marker of vascular inflammation, Lp-PLA2Ò
webcast:
http://www.croiwebcasts.org/console/player/25790?mediaType=slideVideo&
Janet Lo, Michael Lu, Ezinne Ihenachor, Jeffrey Wei, Sara Looby, Kathleen Fitch, Suhny Abbara, Gregory Robbins, Udo Hoffmann,
Steven Grinspoon
Massachusetts General Hospital
Harvard Medical School
Paris, Paris, France
Target to background ratio of FDG uptake in the aorta did not appear to change with statin therapy, however, we really cannot make a definitive conclusion due to technical limitations we faced using manual co-registration of PET and CT images of identical anatomical regions serially over time. Only 21 pairs of the co-registered scans were of acceptable image quality and thus greatly reducing our ability to analyze this endpoint.
*Calculated using CKDEPI formula. eGFR decreased significantly within the placebo group (p = 0.03), but not the Atorvastatin group (p = 0.83).
|
| |
|
|
|
|
|
